CTBP2 and ovarian carcinoma: A recent report also showed that increased miR-101 levels are negatively associated with the overall survival (OS) and disease-free interval (DFI) in patients with ovarian carcinoma and miR-101 could target C-terminal binding protein-2 (CtBP2) to enhance the stemness of cancer cells29.